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Abstract
Limited information is available on the brain expression and role of GPR35, a Gi/o coupled receptor activated by
kynurenic acid (KYNA). In mouse cultured astrocytes, we detected GPR35 transcript using RT-PCR and we found
that KYNA (0.1 to 100 µM) decreased forskolin (FRSK)-induced cAMP production (p<0.05). Both CID2745687 (3 µM,
CID), a recently described GPR35 antagonist, and GPR35 gene silencing significantly prevented the action of KYNA
on FRSK-induced cAMP production. In these cultures, we then evaluated whether GPR35 activation was able to
modulate intracellular Ca2+ concentration ([Ca2+]i ) and [Ca2+]i fluxes. We found that both KYNA and zaprinast, a
phosphodiesterase (PDE) inhibitor and GPR35 agonist, did not modify either basal or peaks of [Ca2+]i induced by
challenging the cells with ATP (30 µM). However, the [Ca2+]i plateau phase following peak was significantly
attenuated by these compounds in a store-operated Ca2+ channel (SOC)-independent manner. The activation of
GPR35 by KYNA and zaprinast was also studied at the CA3-CA1 synapse in the rat hippocampus. Evoked excitatory
post synaptic currents (eEPSCs) were recorded from CA1 pyramidal neurons in acute brain slices. The action of
KYNA on GPR35 was pharmacologically isolated by using NMDA and α7 nicotinic receptor blockers and resulted in a
significant reduction of eEPSC amplitude. This effect was prevented in the presence of CID. Moreover, zaprinast
reduced eEPSC amplitude in a PDE5- and cGMP-independent mechanism, thus suggesting that glutamatergic
transmission in this area is modulated by GPR35. In conclusion, GPR35 is expressed in cultured astrocytes and its
activation modulates cAMP production and [Ca2+]i. GPR35 activation may contribute to KYNA effects on the
previously reported decrease of brain extracellular glutamate levels and reduction of excitatory transmission.
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Introduction
The G protein coupled receptor 35 (GPR35) was identified
approximately 15 years ago [1], but its endogenous ligand as
well as its role both in physiology and pathology are still not
clear [2]. However, it is clearly demonstrated that GPR35 is
expressed in the immune and gastro-intestinal systems, dorsal
root ganglia (DRG), spinal cord, brain and cerebellum [3–5]
and that zaprinast, a well-known cGMP PDE inhibitor [4], and
kynurenic acid (KYNA) [5], a tryptophan metabolite, may
activate this receptor. We have been particularly interested in
studying the action of KYNA because of its ability to interact
with different targets [6,7] and its proposed involvement in
schizophrenia [8,9], cerebral ischemia [10] and degenerative
neurological disorders [11]. We assumed that KYNA is the
endogenous ligand for this receptor. However, the apparent
low affinity of KYNA for the human form of the receptor and
findings that other endogenous compounds such as
lysophosphatidic acid may activate GPR35 with relatively high
affinity [12] questioned this assumption [13]. A number of
compounds such as pamoic acid [14], cromolyn disodium [15]
and tyrphostin analogs have been recently described as
GPR35 agonists [16,17].
KYNA has a number of other targets in the brain: it is a
potent antagonist of the glycine allosteric site on the NMDA
receptor complex and for several years it was assumed that the
interaction between KYNA and the NMDA receptor could have
a physiological role in brain function [18]. It has also been
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demonstrated that KYNA antagonizes α7 nicotinic receptors
that are mostly located on pre-synaptic terminals [19] and it has
been proposed that the reduced levels of glutamate in brain
extracellular spaces found in KYNA treated animals are due to
inhibition of these receptors. However, KYNA affinity for α7
nicotinic receptor is still rather low (µM) and certainly not in the
range of the concentrations able to reduce glutamate release
(low nM). Furthermore, other α7 nicotine receptor antagonists
have some, but not all the actions of KYNA on excitatory
transmitter release [20]. Thus, the reduction of glutamate
concentration in the extracellular spaces cannot be exclusively
ascribed to KYNA interaction with α7 nicotinic receptors and
GPR35 remains one of the possible KYNA targets.
In previous studies, we reported that GPR35 is abundantly
expressed in the DRG and the spinal cord of the rodents and
that experimental elevation of KYNA concentration in the blood
or brain significantly decreased glutamate extracellular levels in
the nervous tissue and reduced inflammatory pain [21]. Since
zaprinast (and other GPR35 agonists) had actions comparable
with those of KYNA and the maximal effects of KYNA and
zaprinast were not additive, we proposed that GPR35
activation was one of the mechanisms whereby KYNA reduced
glutamate concentrations in brain extracellular levels and this
could significantly decrease pain-activated neurotransmission
[6,21].
In the present studies we firstly focused our attention on
cultured astrocytes and we studied the effects of KYNA and
zapinast on GPR35 activation, cAMP accumulation and
calcium transients. A reduced intracellular cAMP concentration
has been shown to modulate intracellular Ca2+ regulatory
mechanisms in non-excitable cells [22]. We found that KYNA
and zaprinast reduced FRSK-induced accumulation of cAMP
and changed the shape of intracellular Ca2+ transients in
astrocytes. Since it is widely accepted that astrocytic G-protein
coupled receptors can tune synaptic transmission by
modulating glutamate release in the synaptic cleft [23], we then
investigated, in brain slices, the effects of KYNA and zaprinast
on excitatory synaptic transmission. The results suggest that
KYNA-induced activation of astrocytic GPR35 could contribute
to the inhibitory action exerted by this tryptophan metabolite on
excitatory synaptic function.
Methods
Ethical Statement
All animal manipulations were carried out according to the
European Community guidelines for animal care (DL 116/92,
application of the European Communities Council Directive
86/609/EEC). Formal approval to conduct the experiments
described has been obtained from Italian Ministry of Health,
according to DL 116/92. All efforts were made to minimize
animal sufferings and to use only the number of animals
necessary to produce reliable scientific data. No alternatives to
animal experimentation are available for this type of
experiments.
Materials
6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX), D(-)-2-
amino-5-phosphonopentanoic acid (D-APV or DL-APV used at
50 or 100 µM, respectively), methyl-lycaconitine (MLA),
gabazine, bicuculline, zaprinast sildenafil, MRS 1845 and Rp-8-
Br-PET-cGMPs were obtained from Tocris (Bristol, UK). QX
314 was from Alomone laboratories (Jerusalem, Israel).
Kynurenic acid (KYNA) and 3-isobutyl-1-methylxanthine (IBMX)
were from Sigma-Aldrich (Milano, Italy). Methyl-5-[(tert-
butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-
difluorophenyl)pyrazole-4-carboxylate (CID) was from Ryan
Scientific (Mt Pleasant, SC, USA). Tissue culture reagents
were obtained from Gibco-BRL (San Giuliano Milanese, MI,
Italy) and ICN Pharmaceuticals (Opera, Milano, Italy). Unless
otherwise declared, all cell culture media were purchased from
Sigma-Aldrich.
Preparation of mouse Dorsal Root Ganglia (DRG) and
cortical astrocytes
DRG were prepared from neonatal mice (P7-P14) as
described previously [24]. Cultured astrocytes were prepared
as described previously [23]. Briefly, cerebral cortices from P0–
P3 mice were dissected free of adherent meninges, minced
and dissociated into a single cell suspension by trituration
through a Pasteur pipette. Cells were grown in Dulbecco's
modified Eagle's medium (DMEM; Gibco, cat. no. 11960-044)
supplemented with 25 mM glucose, 10% heat-inactivated horse
serum, 10% heat-inactivated fetal bovine serum, 2 mM
glutamine and 1000 units/ml penicillin–streptomycin. Cultures
were maintained at 37°C in a humidified atmosphere with 5%
CO2. These cultures contain a high percentage of viable
astrocytes (>90%), as previously demonstrated with by means
of glial fibrillary acidic protein (GFAP) immunostaining [23].
GPR35 detection by semi-quantitative and real time RT-
PCR
RNA from DRG and astrocytic cultures was prepared using
miRNeasy mini spin columns (Qiagen, Milano, Italy). cDNA
was synthesized using equal amounts of RNA in each reaction
(iScriptTM cDNA Synthesis Kit BIO-RAD, Milano, Italy). GPR35
mRNA levels were determined by semi-quantitative PCR
performed with a Biometra thermal cycler (Gottingen,
Germany), with the following amplification protocol:94°, 56°,
72°, (25 cycles), using the following primer pair: 5’-
GGGGTACTGGCTCTCCCTAC-3’ and 5’-
CCCAAGAGTCAACGTGCTTT-3’ (Integrated DNA
Technologies, Leuven, Belgium). The ribosomal RNA 18S was
amplified as an internal control. For real time PCR, RNA was
extracted and reverse-transcribed as described above. The
same primer pair was used and PCR was performed wih the
Sybr Green kit (Qiagen) in a Rotorgene 3000 cycler system
(Corbett Research, Australia).
GPR35 silencing in cultured astrocytes.  Small interfering
RNAs (siRNAs) used for GPR35 silencing in cultured
astrocytes were purchased from Qiagen (Mm_Gpr35_10
siRNA, FlexiTube siRNA). The sequence of negative control
siRNA (non silencing) was 5′-UUCUCCGAACGUGUCACGU-3′
(Qiagen). RNA was dissolved in the accompanying buffer and
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then in serum-free, oligofectamine-containing medium
according to the manufacturer's instruction (Invitrogen, San
Giuliano Milanese, Italy). Cells at 40-50% confluence were
exposed to siRNA for 4 h at 37°C, and then an appropriate
volume of DMEM plus serum was added to restore normal
serum concentration (10%). After 48 h; astrocytes were
processed for cAMP detection experiments (below) [21]..
Effective GPR35 mRNA silencing was assessed with real-time
PCR as described above.
Determination of cAMP levels in cultured astrocytes
After ten days of culture in 24 well-plates, astrocytes were
incubated with MEM/HEPES 10 mM for 10 min and then
stimulated for 30 min with FRSK 10 μM in presence of IBMX
100 μM. KYNA or zaprinast were added in MEM containing
HEPES. GPR35 antagonist (CID) was added 15 minutes prior
to KYNA application. Reaction was stopped with lysis buffer
from the Promega cAMP Glo assay kit and the plate shaken for
45 min at room temperature. cAMP level determination was
performed with a VICTOR plate reader (Perkin Elmer).
Imaging of fluo-3 fluorescence in cultured
astrocytes.  Cultured astrocytes were incubated in a solution
containing (mM): 150 NaCl, 10 HEPES, 3 KCl, 2 CaCl2, 1
MgCl2, 10 glucose (pH adjusted to 7.3) at 37°C for 30 min with
the acetoxymethyl (AM) ester of fluo-3 (fluo-3 AM, 10 μg/ml;
Molecular Probes, Milano, Italy). To aid solubilisation of fluo-3
AM in aqueous medium, we added pluronic F-127 (1 mM;
Molecular Probes). The dye was then allowed to de-esterify for
30 min at room temperature. Coverslips containing fluo-3-
loaded cells were subsequently transferred to a continuously
perfused (2 ml/min) microscope stage for imaging. Images
were visualized with a 20X/0.5W Fluor objective (Nikon) and
acquired every 2 to 30 seconds accordingly to the temporal
resolution needed. Exposure time was set to 25 to 50 ms and
excitation was provided by 450-490 nm filtered light from a
mercury lamp. Fluorescence was detected through a band
pass filter (510-560 nm) with a Photometrics Coolsnap HP
Camera set at -20°C. Fluorescence intensity was measured in
cell bodies using Imaging Workbench 5 software (Indec
BioSystem) and expressed as the ratio of (F - F0)/F0, where F0
is the fluorescence intensity before drug treatment. All
measurements were corrected for the background
fluorescence. Increases in fluorescence ratio greater than 0.2
were considered to be significant changes. Two ATP
applications were performed in order to obtain an internal
control. Drugs were applied before the second ATP response.
The first peak obtained was then normalized to 100% and the
area under the curve (AUC) of the second ATP response was
calculated in control and in the presence of different drugs in a
time period from 20 s to 70 s after the IP3-induced peak. The
KYNA effect on capacitative calcium entry (CCE) was
measured and compared to the one produced by the CCE
selective blocker MRS 1845 after adding different
concentrations of the drug to a calcium free solution where
previous addition of the Sarco/Endoplasmatic Reticulum
Calcium ATPase (SERCA) blocker thapsigargin had completely
depleted the astrocytes calcium internal stores [25]. A rapid
change from 0 mM Ca2+ solution to 2 mM Ca2+ solution
produced an increase in cytosolic Ca2+ concentration due to
CCE [26]. All experiments were performed at room temperature
(20–23°C).
Preparation of acute hippocampal slices and
electrophysiological recordings.  Preparation of
hippocampal slices was carried out as previously described
[23,27]. Young rats (Sprague-Dawley, age P14-P20) were
deeply anesthetized with isoflurane and killed by decapitation.
The brain was rapidly removed and submerged in an ice-cold
artificial cerebrospinal fluid (ACSF) with the following
composition (mM): 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25
NaH2PO4, 1 CaCl2, 3 MgSO4 and 10 glucose saturated with
95% O2/5% CO2, at pH 7.4. The hemisected brain was glued
onto the stage of a vibrating micro-tome (Vibratome 1000s,
Leica) and sections of 300 µm thickness were cut and stored in
an incubation chamber at room temperature for about 1 h
before use. The University of Florence Institutional Animal Care
and Use Committee (IACUC) approved all procedures.
Conventional visually-guided whole-cell patch recordings were
obtained from CA1 pyramidal neurons in voltage clamp
configuration using a Multiclamp 200 B (Molecular Devices,
Sunnyvale, CA, USA) and a pipette with a resistance of 5-7
MΩ. The standard recording solution was composed of (mM):
130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 1.5 CaCl2, 1.5
MgSO4 and 10 glucose saturated with 95% O2/5% CO2, at pH
7.4. All neurons included in this study had a resting membrane
potential below –55 mV and an access resistance in the range
of 10-20 MΩ that showed only minimal variations during the
recordings included in this study. Recordings were filtered at 5
kHz and digitized at 20 KHz using a Digidata 1322A A/D board.
All data were acquired, stored and analyzed on a PC using the
pCLAMP, Origin and Graphpad Prism software (Molecular
Devices, Sunnyvale, CA, USA and Microcal Software,
Northampton, MA, USA, respectively). Drugs were
administered by addition to the superfusing medium and were
applied for a sufficient period to allow their full equilibration. All
the data were collected at room temperature (23-26°C).
Measurement of evoked EPSCs (eEPSCs).  For recording
of eEPSCs, electrodes were filled with (in mM) 140 K-
gluconate, 10 HEPES, 7 NaCl, 4 Mg-ATP and 0.3 Na3-GTP.
EPSCs were evoked from a holding potential of –60 mV by
stimulation at a frequency of 0.06 Hz [28]. Stimuli were
delivered through a bipolar stimulating electrode (240 µm
spacing, FHC Inc., Bowdoinham, ME, USA) placed in the
stratum radiatum within 100 µm of the patched cell. To avoid
recurrent excitation, CA3 pyramidal layer was removed with a
scalpel blade. 10 µM gabazine was used to abrogate GABAA-
mediated inhibitory synaptic activity. D-APV (50 µM) and MLA
(10-100 nM) were pre- and co-applied with KYNA in order to
occlude the effects of KYNA on NMDA and α7 nicotinic
receptors, respectively. In some experiments, GPR35
antagonist CID (10 µM) was included in the mix.
Statistics.  Pooled data throughout the paper are presented
as mean ± standard error (SEM) of n independent experiments
(in parentheses in bar graphs). Sigmoidal dose-response curve
(variable slope) was used to fit KYNA induced reduction of
FRSK-induced cAMP production at different concentration.
Unless otherwise specified, statistical difference between
GPR35 Modulation of Neurotransmission
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means is assessed with a two-sample Student t-Test for
unpaired data (GraphPad Prism 5.0). Significance at the p <
0.05, 0.01 and 0.001 level is indicated with *, **, ***,
respectively in figures. When traces are shown, they are
intended to represent typical observations. Graphs, histograms
and fittings were generated in GraphPad Prism 5.0.
Results
Identification of GPR35 in astrocytic cultures
For the determination of GPR35 expression in cortical
astrocytic cultures, we employed a semi-quantitative RT-PCR
analysis. Figure 1A shows that a PCR product of the predicted
size of 230 bp was amplified using cDNA generated from
cultured astrocytes and DRG, a preparation rich in this
receptor. Using immunohistochemistry, we previously reported
that astrocytes express the protein in the cytosol and
membranes, but not in the nucleus [29]. We then tested the
effects of the putative GPR35 agonists KYNA and zaprinast on
FRSK-induced increase of cAMP levels in these cells. This
procedure has been widely used in our laboratory to study the
action of Gi/o coupled receptors [30,31]. We found that both
KYNA and zaprinast (at low concentrations) significantly
reduced FRSK-induced cAMP accumulation (Figure 1B and
inset). Interestingly, CID, a compound reported to be able to
antagonize KYNA on mouse GPR35 [14], prevented the effects
of KYNA on FRSK-induced cAMP formation (Figure 1C).
Finally, using siRNA, we were able to significantly reduce
GPR35 transcript levels (Figure 1D) with a transcript decrease
of about 50% compared to scrambled siRNA (Figure 1E) and
prevent KYNA-induced reduction of FRSK-dependent cAMP
formation (Figure 1F).
GPR35 and [Ca2+]i in astrocytes
Activation of Gi protein-coupled receptors in astrocytes may
reduce cAMP signaling pathways and modulate intracellular
Figure 1.  GPR35 is expressed in mouse cortical astrocytes and its activation provokes a decrease of FRSK-induced cAMP
production.  A) GPR35 transcripts were detected in cultured mouse astrocytes and in DRG after 10 days of in vitro cultures by RT-
PCR. Ribosomal 18S RNA was amplified as an internal control. PCR products were analyzed by means of agarose gel
electrophoresis. B) Concentration-response curve of KYNA on FRSK-activated cAMP formation in mouse astrocytic culture. Inset:
zaprinast (1 µM), a different GPR35 agonist, induces a decrease of FRSK-activated cAMP formation. C) CID, prevents KYNA
effects on FRSK-activated cAMP formation. D, E and F) GPR35 mRNA silencing reduces RNA expression and abolishes KYNA (10
µM) effects on FRSK-activated cAMP formation.
doi: 10.1371/journal.pone.0082180.g001
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Ca2+ waves through a number of molecular mechanisms
[32–34]. Agonist-induced Ca2+ signaling events in astrocytes
typically consist of two phases: release of Ca2+ from internal
stores (mainly the endoplasmic reticulum), which leads to a
second phase of sustained Ca2+ entry across the plasma
membrane. Therefore, we studied if and how GPR35 agonists
could modify calcium waves induced by exposing cultured
astrocytes to ATP (30 µM), which releases Ca2+ from internal
stores by activating purinergic adenosine receptors 2+[32].
Figure 2A and 2B shows the effects of ATP on [Ca2+]i and the
modulation of this effect in the presence of the GPR35 agonist
KYNA. GPR35 activation decreases the plateau phase of the
increase of [Ca2+]i following an IP3 mediated stimulus (ATP 30
µM) (Figure 2A, B and C). Interestingly, also zaprinast induced
a decrease of [Ca2+]i plateau phase similar to the one obtained
with KYNA, thus strengthening the proposition of a GPR35-
mediated activation of this effect (Figure 2 C and D).
One of the mechanisms controlling the duration of the
plateau phase of the waves is the opening of the so called
“store operated calcium channels” after the IP3-induced Ca2+
release from the stores. This influx has also been named
capacitative Ca2+ entry and in cultured cerebellar astrocytes is
modulated by cAMP intracellular concentrations [22]. It is
possible to reduce this influx with MRS-1845, and Figure 2 E
and F show that the compound has a non-quantitative action
comparable to that of KYNA. In order to rule out the possibility
that the measeured effect is due to antagonism of NMDA or on
α7 nicotinic receptors we also tested D-APV (100 µM) and MLA
(100 nM) which antagonize NMDA or α7 nicotinic receptor,
respectively. Figure 2E and 2F show that neither NMDA nor α7
nicotinic receptors antagonists modify calcium waves in
astrocytes.
Since cAMP has been reported to increase capacitative
calcium entry (CCE) and to modulate the length of the plateau
phase of the Ca2+ signaling in astrocytes [22] and the actions of
MRS-1845, an inhibitor of this influx, resemble those of KYNA
and zaprinast, we used a specific protocol to investigate
whether GPR35 activation with KYNA could reduce this
calcium influx. Figure 3 reports that in astrocytes exposed to
nominally Ca2+ free medium thapsigargin depletes Ca2+ stores
passively by virtue of its ability to inhibit SERCA pumps on the
endoplasmic reticulum and the ensuing entry of Ca2+ is
therefore assumed to be the very definition of CCE [25,26]. The
actions of appropriate concentrations of KYNA or of MRS1845
on these channels are rather different: MRS inhibits while
KYNA does not affect this influx. These experiments rule out
the possibility that GPR35 activation and the resulting reduced
cAMP in the cells modify the plateau phase of calcium
signaling by inhibiting SOCs.
GPR35 activation reduces synaptic transmission at
CA3-CA1 synapses
Previous studies demonstrated that KYNA reduces brain
extracellular glutamate concentrations and that this action
cannot be completely ascribed to NMDA or α7 nicotinic
receptors [20]. It has also been reported that KYNA may inhibit
excitatory transmission to CA1 pyramidal neurons not only
through α7 nicotinic or NMDA receptors, but also through other
mechanisms that remain to be identified [35]. In order to study
KYNA effects on CA3-CA1 evoked excitatory post synaptic
current (eEPSC), KYNA was applied after pharmacological
blockade of both α7 nicotinic and NMDA receptors. Under
these experimental conditions, KYNA 30 µM still reduced
eEPSC suggesting that other mechanisms were involved in this
action (Figure 4A black dots and B). Lower KYNA
concentrations (1 and 10 µM) were ineffective in this paradigm
(data not shown) suggesting a ceiling effect of KYNA 30 µM
which does not inhibit AMPA receptor mediated current as
previously reported [36]. Therefore, we hypothesized that
GPR35 could be involved and to test this proposal, we studied
the effects of KYNA in the presence of CID (10 µM), a recently
described GPR35 antagonist. CID pre-incubation was able to
antagonize KYNA effect on eEPSCs at CA3-CA1 synapse
(Figure 4A red dots and B) thus suggesting a GPR35-mediated
effect of KYNA in reducing eEPSC amplitude. It is interesting to
notice that neither MLA nor APV significantly reduced eEPSC
(Figure 4A and B). Moreover, the effects of zaprinast in the
same preparation were tested. Zaprinast decreased eEPSCs
(Figure 5A) and, in order to rule out the possibility that
zaprinast actions were mediated through PDE inhibition and
activation of the NO-cGMP- protein kinase (PKG) pathway as
previously reported [37,38], we performed experiments in the
presence of Rp-8-Br-PET-cGMPS, a PKG inhibitor. Under
these experimental conditions, zaprinast still reduced eEPSC
amplitude therefore suggesting a mechanism independent from
PKG activation (Figure 5C and D). Finally, sildenafil, another
potent and selective inhibitor of PDE5, did not modify eEPSC,
thus confirming that PDE5 inhibition is not responsible for
zaprinast-induced eEPSCs reduction (Figure 5B).
Discussion
We found that astrocytes express GPR35 transcript and that
pharmacological activation of this receptor leads to reduction of
i) FRSK-induced cAMP elevation (Figure 1), ii) ATP-induced
Ca2+ transients (Figure 2) and iii) excitatory synaptic
transmission (Figures 4 and 5). Previously, we had reported
that basal extracellular glutamate levels were reduced by
KYNA in in vivo microdialysis experiments [20]. Therefore, it
seems reasonable to propose that glial GPR35 could be an
important player in the modulation of excitatory synapses.
Studies on the molecular mechanism leading from receptor
stimulation to dampening of synaptic transmission could
therefore be helpful to clarify the role of astrocytes in brain
functioning.
As previously mentioned, KYNA is one of the proposed
endogenous ligand for GPR35 and zaprinast, a cGMP
phosphodiesterase inhibitor, is another potent agonist of this
Gi/o coupled receptor [4,5]. In the present study we used both
KYNA and zaprinast in order to link the observed effects to
GPR35 receptor activation. However, since both compounds
are known to interact with a number of other pharmacological
targets, particular care was used to rule out the possibility that
other receptors or enzymes could be responsible for the
observed effects. In fact, beside interacting with GPR35, KYNA
is considered an antagonist of the glycine allosteric site the
GPR35 Modulation of Neurotransmission
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Figure 2.  KYNA and zaprinast decrease the [Ca2+]i plateau phase following an IP3-mediated stimulus in mouse cortical
astrocytes.  A) A typical example of KYNA and zaprinast-induced decrease in somatic fluo-3 fluorescence time course measured in
three different astrocytes in cultures: control (upper panels), in the presence of 10 μM KYNA (middle panels) or zaprinast 1 µM
(lower panels). B and C) Time course of KYNA and zaprinast effects on fluo-3 fluorescence in a single astrocyte in culture. KYNA
and zaprinast were applied 5 min before the recording was started. D) Area under the curve (AUC) of fluorescence intensity plot
following an IP3 induced stimulus in control, KYNA and zaprinast, respectively. E) Time course of MRS-1845, D-APV (50 µM) and
MLA (100 nM) effects on fluo-3 fluorescence in a single astrocyte in cultures. F) AUC following an IP3-induced stimulus in control,
MRS-1845, D-APV and MLA. Area was calculated from 20 to 70 seconds after the ATP-induced fluorescence peak.
doi: 10.1371/journal.pone.0082180.g002
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NMDA receptor complex and for several years it was assumed
that the interaction between KYNA and the NMDA receptor
complex could have a physiological role in brain function [18]. It
was then demonstrated that KYNA antagonizes α7 nicotinic
receptors that are mostly located on pre-synaptic terminals
[19]. KYNA affinity for NMDA or α7 cholinergic nicotinic
receptors are rather low (IC50s are: 10-100 µM) and a number
of other receptor antagonists are available. In each of our
experiments we ruled out the possibility that either α7 nicotine
or NMDA receptors could be involved using saturating active
concentrations of MLA and D-APV to study the possible
involvement of α7 nicotinic or NMDA receptor, respectively.
Concerning the second agonist, zaprinast, which is considered
the standard reference activator of GPR35 [2,4], since it inhibits
PDE (especially 5 and 6), the observation that sildenafil, a
specifc PDE5 inhibitor, did not alter eEPSCs amplitude and
that Rp-8-Br-PET-cGMPs, a PKG inhibitor, did not prevent the
action of zaprinast on eEPSCs, strongly argues in favor of the
involvement of GPR35 in zaprinast-dependent depression of
eEPSPs. We are therefore rather confident that, in these
experimental conditions, the reduction of excitatory synaptic
transmission are the consequence of GPR35 activation.
Previous studies reported that a modest increase of KYNA
extracellular concentrations in the brain is associated with a
number of behavioral effects (reduced locomotor activity, mild
analgesia, control of seizures and prevention of excitotoxic
neuronal damage) suggesting that KYNA may reduce the
activity of brain excitatory transmission at concentrations
unable to interact with NMDA receptors [39–42]. It has also
been demonstrated that a two-threefold elevation of brain
KYNA levels significantly reduces post-ischemic brain damage
in models of focal or global brain ischemia in vivo and in
organotypic hippocampal slice cultures exposed to oxygen and
glucose deprivation in vitro [43]. An increase of brain KYNA
levels may be obtained by administering direct or indirect
precursors, transport inhibitors or inhibitors of kynurenine 3-
monooxygenase (KMO) the most abundant of the kynurenine
metabolizing enzymes. No matter of the approach used, a mild
increase of brain KYNA concentration reduces excitatory
transmission and this may be evaluated with biochemical,
electrophysiological, histological or behavioral methods [44,45].
Recently, a very elegant study reported that inhibition of
kynurenine 3-monooxygenase in peripheral organs, by
increasing blood kynurenine levels and brain KYNA content,
significantly reduced neurodegeneration in different transgenic
models of Huntington’s and Alzheimer’s diseases [46]. Similar
results have been obtained in a drosophila model of Huntington
chorea [47]. KYNA is mostly formed in astrocytes [48] and a
local increase of its extracellular concentration drastically
reduces extracellular brain glutamate content [20,49], although
in different brain areas. A reduction of astrocytic glutamate
output could contribute to the robust decrease of excitatory
transmitter levels in brain extracellular spaces associated with
increased KYNA synthesis [20] and could explain most of
behavioral, electrophysiological and neuroprotective effects of
KYNA. The molecular mechanisms leading from KYNA-
Figure 3.  KYNA-induced decrease of [Ca2+]i plateau phase following an IP3-mediated stimulus is CCE-independent.  A)
Time course of Ca2+ fluxes following an IP3–mediated stimulus (external Ca2+ concentration, [Ca2+]e, 2 mM), a depletion of internal
Ca2+ stores induced by thapsigargin in 0 mM [Ca2+]e and subsequent stores refilling (CCE) induced by restoring 2 mM [Ca2+]e . B)
AUC following reinstatement of 2 mM [Ca2+]e showing the modulation of CCE by the selective SOC blocker MRS -1845 but not by
KYNA 10 µM.
doi: 10.1371/journal.pone.0082180.g003
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induced activation of GPR35 to the reduced glutamate output
from astrocytes could well include a reduced cAMP formation
and a decrease of Ca2+ transients (Figure 2). While the
molecular mechanism leading from the stimulation of a
receptor coupled to Gi/o to a decrease cAMP synthesis have
been widely investigated and are sufficiently elucidated, the
mechanisms leading to changes in the Ca2+ transients and
reduced transmitter output remain to be clarified. A number of
possible cross-talk pathway between cAMP and Ca2+ signaling
have been described and could be operative in our model
[50,51]. In astrocytes, in particular, it was proposed that
changes in cellular cAMP concentration may modulate CCE
[22]. Therefore, we focused our attention on this current and
we found that the actions of either KYNA or zaprinast on the
plateau phase of ATP-induced Ca2+ transients were
qualitatively similar to those of MRS 1845 a selective inhibitor
of the store operated channels which are responsible for this
current. When SOCs were studied with a specific protocol (see
Figure 3) we noticed that the action of KYNA and those of MRS
could be easily differentiated, thus ruling out the possibility that
the effects of GPR35 activation on the plateau phase of ATP-
induced calcium transients could be ascribed to changes of the
capacitative calcium entry. The effects of GPR35 activation on
Ca2+ transients remain therefore to be clarified. In excitable
cells, such as rat sympathetic neurons, expressing transfected
GPR35, it has been shown that GPR35 agonists modulate the
voltage operated calcium channels of the N-type which are
obviously involved in controlling transmitter release [52]. In
astrocytes the N-type channels are not expressed and the
mechanism controlling the Ca2+ sources involved in exocytotic
glutamate release remain to be clarified [53]. It is clear,
however, that GPR35 agonists modulate astrocytic Ca2+ fluxes,
transmitter release and synaptic transmission. It is also well
demonstrated that by selectively stimulating nearby astrocytes
it is possible to modify synaptic currents and regulate neuronal
plasticity [54]. Our data, by demonstrating that both KYNA and
zaprinast decrease excitatory synaptic currents strongly
suggest that astrocytic receptors may control the levels of
synaptic transmitter and the function of neuronal circuits.
GPR35 mediated effects were studied both in mouse and rat
and the overall results suggest a KYNA-induced GPR35 effect
in both species. KYNA GPR35 mediated effects on eEPSCs
were tested in rats were KYNA actions on synaptic
transmission were better characterized [35]. Finally, our
observation suggest that GPR35 may be an interesting
pharmacological target since GPR35 agonists could have a
role in decreasing pain transmission [29] and reducing
excitotoxic damage in a number of clinical conditions [6,7,11].
Figure 4.  KYNA reduces eEPSCs amplitude at CA3-CA1 synapse in a GPR35 dependent manner.  A) Time course of KYNA-
induced decrease in eEPSC amplitude, normalized to pre-application values, in the presence of D-APV and MLA (50 µM and 100
nM, respectively; black dots), or D-APV, MLA and CID (10 µM; red dots). Sample traces are shown on top. B) Bar graph shows
maximal effect of KYNA and its antagonism by CID. The effect of KYNA was statistically significant compared to pre-application
level (third vs second column, One-Way ANOVA for repeated measures, followed by Tukey’s post hoc test). Preincubation with CID
was able to prevent the effect of KYNA (fourth vs third column, two-way t-test for unpaired sets of data).
doi: 10.1371/journal.pone.0082180.g004
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Figure 5.  Zaprinast reduces eEPSC amplitude at CA3→CA1 synapse in a PDE5-and cGMP-indipendent manner.  A and C)
Time course of the zaprinast-induced decrease in eEPSC amplitude alone (A) and in the presence of Rp-8-Br (a cGMP-dependent
protein kinase-PKG- inhibitor). EPSCs are normalized to pre-application amplitude values. Sample traces (at top) were obtained
before (left) and during (right) zaprinast application and represent averages of 5 traces. Rp-8-Br was pre incubated for at least 10
min before zaprinast application. B) Time course of the effect of sildenafil (a PDE5 inhibitor) showing no effect on EPSC amplitude.
Sample traces (at top) were obtained before (left) and during (right) sildenafil application and represent averages of 5 traces. D) Bar
graph of maximal effect of zaprinast application, with or without Rp-8-Br, and sildenafil.
doi: 10.1371/journal.pone.0082180.g005
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